CSNK1A1 and myelodysplastic syndrome: Nevertheless, the degradation of CK1α provides a mechanistic basis for lenalidomide’s unique clinical efficacy in myelodysplastic syndrome (MDS) patients with deletion of chromosome 5q (del(5q))11.